While current data suggest that tumor mutational burden (for UC), PD-L1 staining, IMDC risk score (for RCC), and certain histologic features may provide insights into ICI response rate, these data are not sufficiently accurate or precise to be used as predictive biomarkers in clinical practice [45]. This evidence concerns the gene CD274 and renal cell carcinoma.